Sean “Diddy” Combs would have a hard time launching a comeback despite his acquittal on the most severe charges because of ...

Merck Mercuriadis aims to buy back the music rights he sold to the private equity firm while building a new investment ...

Merck Mercuriadis, the architect behind Hipgnosis’s transformation of music rights into a mainstream asset class, is making a ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

Hipgnosis, which Mercuriadis launched in 2018 to buy song rights and was sold last year, is back with bigger ambitions.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Merck Foundation Chairman, CEO with First Ladies of Africa & Asia at 7th Edition of Merck Foundation First Ladies Initiative ...

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

From health to hair care, the experts broke down exactly how artificial intelligence is shaping Black futures and why we can’t afford to sit this one out.

SCHD's quality-focused approach sets it apart from other high-yield ETFs, as it focuses on financial strength and strong ...

This was followed by Merck & Co’s Keytruda (pembrolizumab) and a gang of rival PD-L/PD-L1 checkpoint inhibitors, which have set new standards in cancer care in many different forms of the disease.